...
首页> 外文期刊>BJU international >Expression of angiopoietin-1 and -2, and its clinical significance in human bladder cancer.
【24h】

Expression of angiopoietin-1 and -2, and its clinical significance in human bladder cancer.

机译:血管生成素-1和-2的表达及其在人膀胱癌中的临床意义。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE To investigate the relationship between angiopoietin-1 and -2 expression and the clinicopathological variables and clinical outcome in patients with bladder cancer treated by surgical resection, as both have been recently identified as antagonistic angiogenic factors which regulate tumour growth. MATERIALS AND METHODS The expression of angiopoietin-1 and -2 were assessed by immunohistochemistry in tissue sections from 52 transitional cell carcinomas of the bladder (33 grade 1, 15 grade 2, four grade 3, including two associated with carcinoma in situ; 22 were stage Ta, 19 T1 and 11 T2 tumours). Normal bladder specimens were also resected during each operation as controls. The expression angiopoietins were related to the clinicopathological variables of the tumours. RESULTS Positive immunostaining was detected in 18 samples (35%) for angiopoietin-1 and in 23 (44) for angiopoietin-2. There was no significant difference in survival according to tumour angiopoietin-1 status in the patients, but incontrast the overall survival of patients with angiopoietin-2-positive tumours was significantly lower than for those with angiopoietin-2-negative tumours (P < 0.05). Positive angiopoietin-2 expression was significantly correlated with histological grade (P = 0.026), histological stage (P = 0.009) and poor prognosis (P < 0.05). On multivariate analysis, positive angiopoietin-2 expression was an independent negative predictor for survival (P = 0.042). CONCLUSIONS These results suggest that angiopoietin-2 overexpression is associated with tumour progression, thereby indicating a poor prognosis for some patients treated by surgical resection for bladder carcinoma.
机译:目的探讨通过手术切除治疗的膀胱癌患者血管生成素-1和-2的表达与临床病理变量和临床结果之间的关系,因为最近两者均被确定为调节肿瘤生长的拮抗血管生成因子。材料与方法采用免疫组织化学方法评估了52例膀胱移行细胞癌的组织切片中Angiopoietin-1和-2的表达(33例1级,15例2级,4例3级,其中2例与原位癌相关; 22例膀胱癌)。 Ta期,19 T1和11 T2肿瘤)。正常膀胱标本也被切除在每个手术作为对照。血管生成素的表达与肿瘤的临床病理变量有关。结果在血管生成素1的18个样本(35%)和血管生成素2的23个样本(44)中检测到阳性免疫染色。患者的肿瘤血管生成素-1状态在生存率上无显着差异,但与之相反,血管生成素2阳性肿瘤患者的总体生存率明显低于血管生成素2阴性肿瘤的患者(P <0.05) 。血管生成素2阳性表达与组织学分级(P = 0.026),组织学分期(P = 0.009)和不良预后显着相关(P <0.05)。在多变量分析中,血管生成素2阳性表达是生存的独立阴性预测因子(P = 0.042)。结论这些结果表明,血管生成素2的过表达与肿瘤的进展有关,从而表明通过膀胱癌手术切除治疗的某些患者预后较差。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号